Evolus Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Evolus Inc.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Evolus Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Evolus Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Evolus Inc. is EOLS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Evolus Inc. has its primary listing on NASDAQ. You can trade Evolus Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Evolus Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Evolus Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Evolus Inc. or others.